Phase 3 trials in Slovakia: Trial Insights

Filters: Phase: Phase 3 Country / region: Slovakia Clear all

1,356 trials match Source: ClinicalTrials.gov registrations

Trials started per year
Category	Trials
2000	6
2001	9
2002	13
2003	27
2004	17
2005	26
2006	62
2007	66
2008	70
2009	65
2010	69
2011	84
2012	57
2013	63
2014	79
2015	63
2016	53
2017	49
2018	52
2019	52
2020	47
2021	60
2022	50
2023	62
2024	53
2025	59
2026	26

Trials by status
Category	Trials
Completed	910
Terminated	169
Active, not recruiting	147
Recruiting	105
Unknown status	11
Enrolling by invitation	7
Withdrawn	5
Not yet recruiting	2

Top lead sponsors
Category	Trials
Novartis Pharmaceuticals	136
Pfizer	102
AstraZeneca	88
Hoffmann-La Roche	63
Eli Lilly and Company	60
Novo Nordisk A/S	54
Sanofi	50
GlaxoSmithKline	49
Boehringer Ingelheim	48
AbbVie	36

Top conditions
Category	Trials
Diabetes Mellitus, Type 2	130
Colitis, Ulcerative	49
Pulmonary Disease, Chronic Obstructive	47
Diabetes Mellitus	43
Breast Neoplasms	42
Crohn Disease	42
Arthritis, Rheumatoid	33
Asthma	33
Carcinoma, Non-Small-Cell Lung	32
Major Depressive Disorder	32

Trials

Showing 76 to 100 of 1,356. Each trial links to its page on Pharma Observatory.

A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006) NCT06883305Phase 3RecruitingAstraZenecaStarted 2025
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease NCT06819878Phase 3RecruitingHoffmann-La RocheStarted 2025
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin NCT06677060Phase 3RecruitingAstraZenecaStarted 2025
A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer NCT06764485Phase 3Active, not recruitingCelgeneStarted 2025
A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure NCT06742723Phase 3RecruitingAstraZenecaStarted 2025
Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE NCT06679881Phase 3Enrolling by invitationPharvaris Netherlands B.V.Started 2025
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1) NCT06799000Phase 3Active, not recruitingNovartis PharmaceuticalsStarted 2025
A Study of the Efficacy and Safety of Efgartigimod in Patients With Primary Sjögren's Syndrome NCT06684847Phase 3Active, not recruitingargenxStarted 2025
Comparison Between ABP 692 and Ocrevus® (Ocrelizumab) NCT06700343Phase 3Active, not recruitingAmgenStarted 2025
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease NCT06760637Phase 3Active, not recruitingPfizerStarted 2025
A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell Lung Cancer (BENITO Study) NCT06687369Phase 3Active, not recruitingmAbxience Research S.L.Started 2024
Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Therapy-resistant CVU (Phase III) NCT06489028Phase 3Active, not recruitingRHEACELL GmbH & Co. KGStarted 2024
A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults With Multifocal Motor Neuropathy NCT06742190Phase 3Active, not recruitingargenxStarted 2024
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma NCT06664619Phase 3Active, not recruitingTeva Branded Pharmaceutical Products R&D LLCStarted 2024
A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease NCT06679140Phase 3RecruitingPfizerStarted 2024
Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE NCT06669754Phase 3Active, not recruitingPharvaris Netherlands B.V.Started 2024
A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56 NCT06683742Phase 3Active, not recruitingEyePoint Pharmaceuticals, Inc.Started 2024
A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine NCT06616194Phase 3Active, not recruitingPfizerStarted 2024
A Study of Nipocalimab in Reducing the Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) NCT06449651Phase 3RecruitingJanssen Research & Development, LLCStarted 2024
A Study About the Long-Term Safety of TAK-881 in People With Primary Immunodeficiency Diseases NCT06076642Phase 3Active, not recruitingTakedaStarted 2024
Study to Evaluate Avacopan in Combination With a Rituximab or Cyclophosphamide-containing Regimen, in Children From 6 Years to < 18 Years of Age With AAV. NCT06321601Phase 3Active, not recruitingAmgenStarted 2024
A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer. NCT06629779Phase 3RecruitingPfizerStarted 2024
A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1). NCT06551324Phase 3Active, not recruitingPfizerStarted 2024
Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic Drug NCT06641076Phase 3Active, not recruitingMoonLake Immunotherapeutics AGStarted 2024
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4) NCT06585787Phase 3RecruitingKaruna Therapeutics, Inc., a Bristol Myers Squibb companyStarted 2024

1,256 more trials match. See them on Pharma Observatory

A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis NCT06461897Status changeRecruiting to Active, not recruitingOctober 18, 2026
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis NCT06461897Enrollment change675 to 699October 18, 2026
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis NCT06461897Completion date change2030-07-31 to 2029-11-30October 18, 2026
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2) NCT06452277Enrollment change555 to 444October 17, 2026
A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3) NCT07076407Status changeRecruiting to Active, not recruitingOctober 17, 2026

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.

Visit Pharma Observatory